Depression screening after ACS does not change outcomes


Background: Depression after ACS is common and is associated with increased mortality. Professional societies have recommended routine depression screening in these patients; however, this has not been consistently implemented because there is a lack of data to support routine screening.

Dr. Claire Ciarkowski, University of Utah, Salt Lake City

Dr. Claire Ciarkowski

Study design: Multicenter randomized clinical trial.

Setting: Four geographically diverse health systems in the United States.

Synopsis: In the CODIACS-QoL trial, 1,500 patients were randomized to three groups within 12 months of documented ACS: depression screening with notification to primary care and treatment, screening and notification to primary care, and no screening. Only 7.7% of the patients in the screen, notify, and treat group and 6.6% of screen and notify group screened positive for depression. There were no differences for the primary outcome of quality-adjusted life-years or the secondary outcome of depression-free days between groups. Additionally, there was no difference in mortality or patient-reported harms of screening between groups. The study excluded patients who already had a history of depression, psychiatric history, or other severe life-threatening medical conditions, which may have affected the outcomes.

Depression remains a substantial factor in coronary disease and quality of life; however, systematic depression screening appears to have limited population-level benefits.

Bottom line: Systematic depression screening with or without treatment offerings did not alter quality of life, depression-free days, or mortality in patients with ACS.

Citation: Kronish IM et al. Effect of depression screening after acute coronary syndrome on quality of life. JAMA Intern Med. 2020;180(1):45-53.

Dr. Ciarkowski is a hospitalist and clinical instructor of medicine at the University of Utah, Salt Lake City.

Recommended Reading

Heart failure redefined with new classifications, staging
The Hospitalist
MIS-C follow-up proves challenging across pediatric hospitals
The Hospitalist
RECOVERY trial of COVID-19 treatments stops colchicine arm
The Hospitalist
DOACs offered after heart valve surgery despite absence of data
The Hospitalist
CDC data strengthen link between obesity and severe COVID
The Hospitalist
Inpatient sodium imbalances linked to adverse COVID-19 outcomes
The Hospitalist
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
The Hospitalist
Colchicine before PCI for acute MI fails to improve major outcomes
The Hospitalist
Cardiac rehab after cardiac valve surgery associated with reduced mortality
The Hospitalist
High obesity rates in Southern states magnify COVID threats
The Hospitalist
   Comments ()